Construction and Evaluation of China's Advanced Pancreatic Tumor Big Data Center

Pancreatic Neoplasms Clinical Trial

Official title:

Construction and Evaluation of China's Advanced Pancreatic Tumor Big Data Center

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05141656
• Other study ID #: CPOG-CDPC-01
• Status: Active, not recruiting
• Start date: August 31, 2019
• Est. completion date: July 31, 2023

Study information

• Verified date: November 2021
• Source: RenJi Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study is a multi-center observational study. The start time for data collection is August 31, 2019. Patients who have been treated at our institution from August 31, 2019, who were diagnosed with pancreatic tumors on or before August 31, 2019 (diagnosed in our hospital or outside hospitals) would all meet the inclusion conditions of the study and be considered enrollment. Patients' baseline and treatment data will be collected under informed concent. The combination of medical big data governance and the leading technology of the big data platform uses real world data to improve the quality and efficiency of pancreatic tumor diagnosis, treatment and scientific research.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 20000
• Est. completion date: July 31, 2023
• Est. primary completion date: July 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

1. Age = 18, both male and female;

2. Patients with primary pancreatic tumor diagnosed by histology, cytology or imaging;

3. Clinical or pathological staging is locally advanced or metastatic pancreatic tumor (newly diagnosed or after surgery and other treatments);

4. You can accept or have not received surgery, chemotherapy, radiotherapy, local treatment or traditional Chinese medicine for tumors;

5. The subject voluntarily joined the study and signed an informed consent form voluntarily.

Exclusion Criteria:

1. Pancreatic tumors are evaluated as metastatic lesions, not primary tumors of the pancreas.

Related Conditions & MeSH terms

• Pancreatic Neoplasms

Intervention

Other:
• No intervention will be considered in this study.
No intervention will be considered in this study.

Locations

Country	Name	City	State
China	RenJiH	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
RenJi Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	OS	overall survival	5 years
Secondary	DFS	disease free survival	5 years
Secondary	PFS	progress free survival	5 years